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Abstract
Heart disease remains the prevalent cause of premature death and accounts for a sig-
nificant proportion of all hospital admissions. Molecular genetics was integrated quite 
late in cardiology, but introduced new concepts like sarcolemmopathies, cytoskeletal-
opathies, and channelopathies useful to better understand the pathophysiology of the 
development of inherited cardiomyopathies (CMs). As our understanding of the cellular 
and molecular processes involved in the development and progression of heart disease 
improved, new therapeutic targets were identified, as were novel approaches such as 
delivery of genes to replace defective or deficient components and thereby restore struc-
ture or function in a diseased heart. We discuss gene addition strategies in the context 
of monogenic disorders. Moreover, a broader nucleic acid-based modulation of cardiac 
gene expression for the treatment of cardiac diseases might have larger clinical indica-
tions. Inadequate gene delivery remains a potential cause of negative trials. However, 
progress in innovative formulations and clinically relevant ways of administration 
should lead to significant progress in the future. Cardiac gene therapy will be integrated 
into the therapeutic armamentarium for CM and heart failure.
Keywords: cardiomyopathy, heart failure, genetic disease, gene therapy, cardiac 
structure, cardiac function, viral vector, nanoparticles, polymers
1. Introduction: cardiomyopathies
Cardiomyopathies (CMs) refer basically to diseases of the heart muscle, which can be acquired 
or inherited [1]. CMs can affect people of all ages. However, people in certain age groups are 
more likely to have certain types of CMs, as inherited forms predominate in younger indi-
viduals and acquired diseases increase with age [2–8].
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Most frequently, four main clinical forms are described, meaning hypertrophic, dilated, and 
restrictive types as well as arrhythmogenic CM. These diseases have many causes, signs, 
symptoms, and treatments. We exclude ischemic cardiopathies from this overview, and focus 
more precisely on disorders of the heart muscle of non-ischemic origin. This does, however, 
not exclude anomalies of the perfusion of the myocardium, because pathophysiology of these 
diseases is usually complex, interleaving different mechanisms.
Diagnosis of non-ischemic CM is a challenging process that influences patient morbidity 
and mortality. Multiple biomarkers and imaging tools contribute to the adequate ranking 
of the clinical presentation of these diseases. More recently, nuclear magnetic resonance 
(NMR) imaging appeared as a robust diagnostic tool that offers various techniques to assess 
the structure, function, perfusion, and scarring of myocardial tissue, thus providing better 
understanding of the underlying causes of CMs [9–12]. At a molecular level, genotyping 
identifies precisely the causal mutations in inherited forms of CMs. Moreover, a systems 
biology approach can investigate more fully the molecular profiles of different phenotypic 
stages of CM.
From a pathophysiological and diagnostic perspective, it might be useful to consider a stratifi-
cation of CMs slightly different from the clinical classification. Considering the various genes 
that can trigger the development and evolution of a CM, we propose to group inherited dis-
eases as cytoskeletal CMs or cytoskeletalopathies, sarcomeric CMs or sarcomyopathies, and 
finally ion channel CMs or channelopathies.
Different structural alterations of the myocardium contribute in varying degrees to the differ-
ent forms of the diseases, but common features may represent as many therapeutic targets.
The focus of more extensive cellular degeneration is one of the histological hallmarks of CM 
[13,14]. Necrosis is not the only mechanism leading to cell death. Apoptosis, or programmed 
cell death, is a highly regulated and active process that contributes to the maintenance of 
adult cardiac tissue [15]. Myocyte cell death is implicated in the architectural rearrangement 
occurring in the surviving myocardium. This remodelling leads to heterogeneity in the myo-
cardial structure, created by the altered behaviour of non-myocyte cells, particularly cardiac 
fibroblasts, which are responsible for myocardial collagen metabolism and fibrous tissue 
accumulation. It may largely explain the appearance of diastolic and/or systolic myocardial 
failure [15]. Adverse left ventricular remodelling leads to alteration in the structure (dimen-
sion, mass, shape) of the heart that might at the beginning of the process be considered as 
compensatory for the disease process, but at the end will severely impair cardiac function. 
Remodelling is also a prominent feature of electrophysiological properties of the myocar-
dium, translated as clinical presentation such as atrial fibrillation, flutter, complete heart 
block, ventricular ectopic pacing, and tachycardia.
Considering the remodelling process as a deleterious end effect, one can raise the question 
of potential reverse remodelling. Could that be an option for remission or cure of CM? It has 
been shown that prolonged mechanical unloading of failing hearts can preserve myocardial 
contractility but impairs relaxation. Could gene therapy provide new therapeutic options for 
those patients?
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Myocardial remodelling involves not only the cardiomyocytes, but also non-myocyte cells 
and the extracellular matrix. Fibrosis is an essential process in the repair of damaged tissues 
and wounds, but its accumulation in organs and tissues can lead to scarring, organ dysfunc-
tion, and, ultimately, failure. Development of interstitial and perivascular fibrosis of varying 
degrees is observed in most CMs. However, in vivo diagnosis of the extent and distribution 
of fibrosis remains difficult. New approaches such as ultrasound elastographic and cardiac 
NMR techniques might provide appropriate outcome measures to monitor more specifically 
myocardial fibrosis, and thus potential therapeutic effects [16].
Immune mechanisms modulate interstitial fibrosis, cardiomyocyte cell death, and hypertro-
phy, all of which are central processes leading to maladaptive remodelling in response to a 
variety of stimuli. Acute inflammation, as observed in myocarditis, might be out of the scope 
of the present overview, and would need a dedicated review. However, in chronic heart fail-
ure (CHF) patients, a chronic inflammatory activation has long been recognized. Heart failure 
is associated with a wide array of mechanisms subsumed under the term “inflammation.” 
This chronic inflammation harms the myocardium instead of healing it. Gene therapy might 
find new therapeutic targets in this context.
Similarly to the structural modifications of the myocardium, functional alterations contribute 
to the definition of CM. From a perspective of pathophysiology, alterations of preload and 
afterload largely contribute to diastolic/systolic dysfunctions. Pressure–volume relationship 
best defines myocardium alteration beyond the hemodynamic parameters.
Moreover, a more detailed understanding of excitation–contraction coupling reveals new 
targets for innovative therapeutic strategies.
Furthermore, and beyond the triggering causes of CM, as heart muscle becomes weaker over 
time, a common clinical condition described as heart failure develops. From a pathophysi-
ological and therapeutic perspective, heart failure could be considered as a specific disease 
stage, independent of the acquired or inherited origin of CM. Gene therapy could also be 
considered at this stage.
2. Therapeutic options: why gene therapy?
Many medicines are used to treat CM and CHF, but despite this, CM and CHF remain leading 
causes of morbidity and mortality even in developed countries. Correcting hemodynamic 
imbalances, such as fluid control (preload) or vascular resistance control (afterload), remains 
primordial, but cannot change the myocardial contractility per se (Figure 1). Fundamentally, 
determinants of cardiac output are the same as those of myocardial energy consumption. 
Therefore, tackling the problem of decreased contractility raises in parallel the problem of 
increased energy requirements. Several attempts to increase inotropism on a chronic basis led 
to overall negative results because energy consumption exceeded production. Gene therapy 
might offer new therapeutic options. The pressure–volume relationship demonstrates the 
contracting and relaxing portions of the cardiac cycle (Figure 2). The slope of the end-systolic 
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pressure–volume relationship represents the most objective measure of the intrinsic contrac-
tile capacity of the myocardium.
Similarly, management of CHF patients frequently takes advantage of rhythm control (phar-
macologic or pacemakers/implantable cardioverter defibrillator). Gene therapy might repre-
sent a new way to address this topic by recreating new endogenous biological pacemakers 
rather than relying on electronic devices.
Recent clinical trials [17–19] have not only pinpointed the importance of inflammation but 
moreover the therapeutic potentialities of selectively targeting some cytokines. At a preclini-
cal level, glycoprotein-130 (gp130) has been identified as a potential new target [20–22]. It is 
now established that with gp-130, the common receptor of IL-6 is elevated in patients with 
chronic heart failure. Hilfiker-Kleiner et al. have shown that mice carrying a cardio-specific 
mutation of gp-130 have a normal myocardial phenotype at baseline. However, induction of 
an experimental myocardial infaction leads to development of heart failure and increased 
mortality. Moreover, these observations were associated with increased expression of com-
plement-activating mannose-binding lectin [23]. Thus, this animal model suggested a link 
between IL-6 and chronic myocardial injury induced by complement activation.
Cardiac myofibroblasts respond to a large number of proinflammatory cytokines (e.g. TNF-
alpha, IL-1, IL-6, TGF-beta), vasoactive peptides (e.g. angiotensin II, endothelin-1, natriuretic 
peptides), and hormones (e.g. noradrenaline), the levels of which are increased in the remod-
elling heart. Reducing myocardial remodelling specifically via modulatory effects on cardiac 
fibroblasts might represent further new therapeutic targets.
Anticoagulants in the context of CHF are an important therapeutic class for those subgroups 
of patients at high risk for abnormal clotting. Anticoagulation might appear inappropriate for 
Figure 1. Determinants of cardiac output (CO). CO is the resultant of stroke volume, the difference between end-
diastolic and end-systolic volumes times the heart rate. According to the Frank–Starling law, preload influences CO 
positively. With developing heart failure, CO is negatively influenced by afterload. Contractility represents the primary 
inotropic capacity of the myocardium.
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gene therapy, but nucleic acids can interfere in a very selective way with proteins. Targeting 
proteins of the intrinsic pathway of the coagulation might achieve safe and efficient throm-
bus control without the usual risk of bleeding that conventional anticoagulants share. 
Furthermore, one should keep in mind that initiation of the intrinsic pathway is intimately 
linked to inflammation via kinins and complement. Nucleic acid might represent a new class 
of drugs in this context.
Surgery represents an important therapeutic option in the arsenal for managing CM and 
CHF patients. The surgical approach can consist of either specific procedures such as septal 
myomectomy in hypertrophic CM (HCM), coronary artery bypass graft surgery, or more 
generally left ventricular assist devices as a “bridge to transplant” or destination therapy [24]. 
Transplantation remains the reference treatment for end-stage CHF and for people who have 
failed other treatment options. It might be surprising to refer to surgery in the context of gene 
therapy, but one should not forget that most initial clinical trials have included terminally 
Figure 2. Pressure–volume relationship. The pressure–volume curve for the left ventricle is represented as a pressure 
vs. volume plot. The slope of the end-systolic pressure–volume relationship indicates the intrinsic contractile capacity 
of the myocardium independently of the hemodynamic load conditions. Compared to a control curve (dark lines), 
cardiomyopathy (light lines) is characterized by a decreased slope among other hallmarks. Gene therapy would aim at 
preserving or restoring normal contractility.
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ill patients. Thereby, in terms of therapeutic efficiency and risk/benefit ratio, initial evalua-
tions will refer to outcomes of surgical procedures. The gene therapist should be aware of the 
competing therapeutic strategies.
So far, none of the existing treatments have definitively changed the fate of CM and CHF. There 
is thus space for new drug developments and gene therapy might help to solve some of the 
intrinsic hurdles of CM and CHF. For instance, none of the existing treatments really change 
myocardial contractility without excessively increasing oxygen consumption.
Advances in gene transfer vectors, development of new vector delivery methods, and dis-
covery of new gene targets continue to fuel our motivation to use this approach in routine 
bedside care [25,26].
3. Gene therapy
When developing a gene therapy-based medicinal product, one should keep in mind that no 
active substance will become a drug product unless it can be properly formulated and admin-
istered. Compared to more conventional small molecules, gene therapy strategies based on 
nucleic acids are faced with new constraints linked to their chemical nature, the size of the 
molecule, and the coding sequence composition.
Different pharmaceutical designs for gene therapy could be considered. In the context of CM 
and CHF, we will focus more precisely on how to restore the functional allele in the context of 
inherited CM and more broadly how to restore or improve myocardial contractility.
3.1. Inherited CM
In the context of inherited CM, most frequently a monogenic transmission profile has been 
identified, expression profiles being either dominant or more frequently recessive. Sometimes 
CMs are part of a larger clinical context of a systemic myopathy, but usually cardiac and 
neuromuscular disorders are not proportional and thus would need separate and specific 
treatment, even if the genetic origin can be unique.
Considering the situation of the single causative gene acting in a recessive mode, it might be 
tempting to restore a normal phenotype through addition of a functional allele. So conceptu-
ally at this level, gene therapy is mainly derived from gene transfer techniques largely used 
in cell biology by introducing an exogenous sequence of nucleic acids into a eukaryotic cell 
to express new information on these cells. Over time, several independent laboratories have 
demonstrated that the concept of transferring an exogenous gene into the myocardium of 
mammals was possible, leading to the expression of a new protein not coded by the intrinsic 
genes. However, to transform a laboratory technique of gene transfer into a therapeutic option, 
additional steps had to be considered. To assess the therapeutic capabilities of gene transfer, 
protein expression cannot be the primary outcome measure. More subtle integration of the 
pathophysiology of each CM is mandatory. Considering inherited diseases where a certain 
phenotypic latency exists, it was possible to demonstrate that gene transfer of a functional allele 
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was able to delay the onset of an overt CM. More generally, when designing a gene therapy 
strategy, one should consider whether the defective gene should be rescued or whether other 
genes involved in heart failure development and progression should be targeted.
3.2. Preclinical models of CM
Delta-sarcoglycan (dSG)-deficient hamsters represent a well-characterized genetically deter-
mined model of a CM. Phenotypically these animals develop a dilated cardiomyopathy 
(DCM) with terminal heart failure over a rather short time span as they die as mid-aged adults 
[27,28]. From the perspective of gene therapy they represent a very useful model. Beyond 
the clear phenotype, the causal genetic mutation is known, coding sequences are readily 
available, and transmission is autosomal recessive. A single allele correction can correct or at 
least clearly improve the phenotype when administered in young animals [29]. Some authors 
observed even more than a simple phenotypic rescue as the lifespan of these animals seemed 
to increase [30,31].
However, unlike dSG, coding sequences of some normal alleles can be very extensive, the most 
extreme case being dystrophin with a full-length cDNA of more than 11 kb. Several strategies 
can be considered. Given some structural specificities, reengineering of the active pharmaceuti-
cal ingredient (API) can be performed while retaining therapeutic potential. Thus, gene therapy 
should not simply be considered as a substitution of defective alleles. Hence, truncated forms of 
dystrophin have proven to alleviate pathologic phenotypes in several experiment models [32,33].
Similarly, it was possible to show that editing the intrinsic messenger RNA can lead to coding 
of a functional protein. Exon skipping is used to restore the reading frame within a gene. 
The mechanism behind exon skipping is a mutation-specific antisense oligonucleotide. An 
antisense oligonucleotide is a synthesized short nucleic acid polymer that will bind to the 
mutation site in the pre-messenger RNA to induce exon skipping. In the context of Duchenne 
muscular dystrophy (DMD) the genetic mutation that leads to Becker muscular dystrophy 
(BMD) is an in-frame deletion. Exon skipping can induce the expression of a truncated but 
functional dystrophin protein and thus switch the phenotype of some DMD-type mutations 
to the phenotype of a BMD-type mutation [34,35].
Multiple arguments in favour of the feasibility of cardiac gene therapy have been generated 
over time. However, these experiments raise new questions. Most non-clinical studies were 
carried out on well-characterized model-rescuing defective genotypes and avoiding or delay-
ing the development of a pathological phenotype. So referring to clinical settings, this mimics 
mainly presymptomatic situations.
In this setting, gene therapy would basically be a prophylactic option to avoid development 
of a pathological phenotype, but are we ready for a gene therapy that would be mainly pre-
ventive? What would an acceptable risk/benefit ratio be in that case? Ideally in the context of 
preventive medicine, gene therapy of an inherited monogenic disorder should by homolo-
gous recombination correct most if not all of the affected cells without any off-target adverse 
effects. Gene therapy has not yet reached this level of maturity. Nevertheless, this does not 
mean that such options cannot be tested in the future.
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3.3. Heart failure
If gene therapy offers the possibility to interfere intimately and subtly with the molecular 
pathways governing the pathological processes, then introducing genetic material into cells 
should be able not only to compensate for abnormal genes but also to influence pathways 
involved in the development and progression of the disease.
In the context of inherited CMs, we postulate that several steps might occur sequentially. The 
causative genetic defect can be inherited or be a neo-mutation and will trigger a cascade of 
deleterious effects that will lead to the appearance of a patent cardiac disease. Progressively 
the genetic features of heart failure will dominate and one might consider that at a later stage 
these changes will be almost independent of the original genetic defect. Moreover, we might 
consider that genetic modifications at this stage are similar to those that occur in the context 
of acquired CM. While any disease is a potential target for gene therapy, some treatments are 
easier to achieve in the clinic. To test this working hypothesis experimentally, we used mainly 
the same dSG-deficient hamster model. However, to mimic symptomatic disease, animals 
were included at a later age.
Many molecular targets could be considered at this level, but several candidates might be 
more prominent in the present context. We have already discussed the case of gene addition 
of a functional allele in the context of an autosomal recessive disorder. The candidate gene 
will of course depend on a proper identification of the genetic disease involved in the CM. On 
the other side, considering the heart failure phenotype as such, multiple options appear.
Rather basically, we evaluated genes preserving myocardial structure. In the experimental 
setting that we considered as a model, it is known that hamsters develop a DCM. However, 
in some substrains carrying the very same mutation but in slightly different genetic back-
grounds, animals can develop firstly a phase of HCM and have a less severe phenotype. So the 
question became, can we mimic this feature by introducing exogenous genetic information?
Physiologic remodelling is a compensatory change in the dimensions and function of the 
heart in response to physiologic stimuli such as exercise and pregnancy. The remodelling 
process frequently includes increases in myocardial mass. The heart can respond to environ-
mental stimuli by growth (increased myocardial mass) or shrinkage (atrophy) with a rather 
large dynamic range. Remodelling is induced by changes in gene expression, which, in turn, 
alter the expression of key regulatory proteins, the distribution and function of subcellular 
organelles, the size and morphology of individual cells, the properties of the extracellular 
matrix, and ultimately those of the entire organ. IGF-1 is a key player in this context and 
prior to developing a gene therapy option we could demonstrate that administration of a 
recombinant IGF-1 protein can exert several beneficial effects of the cardiac phenotype of 
dSG-deficient hamsters [36,37]. However, a recombinant protein with pleiotropic effects will 
inevitably lead to extracardiac adverse effects. Therefore, a gene therapy option might offer 
a more targeted treatment, especially when associating local delivery with tissue-specific 
regulatory sequences. IGF-1 served as a role model to highlight some of the innovative differ-
ences between gene therapy and conventional treatments, but of course other APIs could be 
developed along a similar strategy. Various pathophysiological processes could be targeted, 
such as interfering with the fibrosis–cell death axis and promoting cell survival.
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Besides structural changes of the myocardium, influencing cardiac function could represent 
further targets for gene therapy strategies. Taking advantage of the well-known hamster 
model, one can reformulate the clinical question as the progressive decline of contractility 
and development of patent heart failure. We considered animals at an early symptomatic 
stage to mimic as closely as possible a clinically relevant situation. We compared the effi-
ciency of administering either a functional cDNA of dSG (rescuing the causal genetic defect) 
or a cDNA coding for a Ca2+-handling protein, for instance SERCA2a. SERCA2a holds a key 
role in the development and progression of heart failure, so after the initial work by Schwartz 
and coworkers, it was rather obvious to test its therapeutic potential [38–40]. Briefly, we 
could demonstrate that from a therapeutic perspective at a clinical stage of patent heart fail-
ure, great benefits could be obtained by targeting cardiomyocyte Ca2+ homeostasis through 
SERCA2a gene expression than rescuing the initial causative genetic defect [41]. These find-
ings as well as results from several other labs strongly support the strategy of cardiac gene 
therapy for heart failure based on restoring appropriate Ca2+ handling [42–44]. At this stage, 
one should cite the pioneering work led by Hajjar that led to a clinical trial (CUPID) using 
an expression cassette coding for SERCA2a [45]. This phase IIa study retained some intrinsic 
limitations due to the low number of patients. Therefore, a larger phase IIb study (CUPID2) 
with a double-blinded, placebo-controlled, and randomized event-driven schema and based 
on multinational, multicenter recruitment (n = 250) was needed to confirm the initial results 
described in the CUPID1 study. This phase IIb CUPID2 trial did not meet its primary and 
secondary endpoints. Nevertheless, multiple useful data were generated by this clinical trial. 
Gene therapy is a realistic therapeutic strategy in the field of CMs. Patient selection is always 
a difficult task in those very innovative steps, but the trial allowed refining the criteria. It 
also became apparent how important formulation of the API and administration are. Before 
discussing these aspects, one should acknowledge the research done by K. Hammond and 
coworkers that explored the therapeutic potential of adenylyl-cyclase type 6 (AC6) [46–48]. 
These authors showed that activation of cardiac AC6 expression improves impaired func-
tion of aged hearts through improved calcium uptake. AC6 determines cAMP formation. 
However, favourable effects on cardiac function through abrogation of hypertrophy, 
increased cell survival, and improved calcium handling appear to be cAMP independent. 
The main goal of the trial based on AC6 administration in CHF patients is to evaluate the 
safety and efficacy of human AC6 gene product as a new therapeutic option. To reach this 
goal, 56 patients were (or have been if the trial is still ongoing - please check) included in 
this study, in which gene delivery was based on a drug formulation where human AC6 was 
carried by an adenovirus serotype 5.
Expression of a peptide inhibitor of GRK2 (βARKct) can improve the contractility of failing 
myocardium and promote reverse remodelling of the left ventricle.
Inhibition with antimiR-34a/antimiR-34 has emerged as a promising therapeutic strategy, as 
silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate HCM. However, 
the beneficial effect does not appear in severe HCM [49]. Thus, it appears important to make 
appropriate staging of the clinical symptomatology, hence the cardiac phenotype. Therapies 
that inhibit miR-34a alone may have limited potential in settings of established cardiac 
pathology [50]. For instance, miR-133, which is enriched in cardiac and skeletal muscle, is 
involved in cell specification, differentiation, and development. Furthermore, miR-a33 is 
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downregulated during cardiac hypertrophy. Specific knockdown of miR-133 via antisense 
targeting can be sufficient for inducing cardiac hypertrophy and reinduction of the foetal 
gene programme [51]. In the context of DCM it might be useful to induce a compensatory 
mechanism by reengaging the foetal gene programme. The miR-22 should also be considered 
as a critical regulator of cardiomyocyte hypertrophy and cardiac remodelling [52]. Systemic 
inhibition of miR-21 has proven effective against myocardial fibrosis and dysfunction [53].
Substantial advances in the understanding of the cellular and molecular basis of CMs and 
CHF highlight the potential utility of gene therapy as a novel therapeutic approach. However, 
successful clinical translation is still limited by the lack of safe, efficient, and selective delivery 
systems.
Naked DNA has remained the preferred method of gene delivery to the myocardium and has 
been explored extensively in clinical trials mainly in the setting of ischemic heart disease. The 
results from these trials have demonstrated efficacy with regards to secondary endpoints of 
reduced symptomatology, but have failed to establish significant increase in angiogenesis or 
an improvement in myocardial function [54].
3.4. Viral vectors for cardiac gene therapy
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types 
while mostly avoiding immunosurveillance by an infected host. Several types of viruses, includ-
ing retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been 
modified in the laboratory for use in gene therapy applications. Adenoviruses are an efficient 
gene delivery system in a broad range of cell and tissue types. However, the adverse immune 
reactions represent an important drawback for its development. Over time, multiple viral vector 
systems have been tested, but more recently AAVs have become most popular. AAVs are non-
enveloped parvoviruses, which can rather easily be engineered to deliver DNA cargo to target 
cells. AAV vectors have demonstrated good potential for in vivo delivery of genetic material into 
various cells, thus appearing as a vector of choice for different therapeutic applications beyond 
cardiac diseases. Nevertheless, and even if some promising clinical outcomes have been reported, 
the current potential of viral vectors for gene therapy still faces significant restrictions, largely 
due to manufacturing challenges, including the absence of an efficient and scalable platform 
purification process [25, 55–58]. At least in the setting of murine models, AAV1, AAV6, AAV8, 
and AAV9 have been identified as the most cardiotropic serotypes after systemic delivery.
The concept of gene therapy seems straightforward, but this is clearly an oversimplifica-
tion, and numerous problems and risks exist that prevent gene therapy using viral vectors. 
Due to the structure of the viral particles, AAV vectors retain limited DNA cargo capacity 
necessitating the need to optimize the therapeutic sequence. Multiple cells can be infected 
by AAVs, but overall the transduction efficiency remains low leading to increased multiplici-
ties of infection, hence putting greater pressure on large-scale vector production. Moreover, 
AAVs’ tropism lacks cell-type selectivity resulting in off-target transduction. Regulation of 
the transgene expression remains difficult and frequently results in decreased expression 
efficiency. Hence, to achieve optimal clinical outcome, high vector doses are required, but 
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the presence of preexisting neutralizing antibodies precludes a number of patients from par-
ticipation. Furthermore, immune elimination of infected cells often limits gene expression in 
vivo. Readministration remains a major challenge, because single shot solutions are counter-
intuitive in the era of precision or personalized medicine. Further work is therefore needed 
to improve viral vectors, more specifically, developing stealthier AAV vectors with the aim 
of optimizing vector–host interactions [59–61]. Low-grade immune stimulation by the vector 
system appears as an important point in terms of drug development to avoid severe adverse 
reactions.
3.5. Non-viral vectors for cardiac gene therapy
Optimal gene therapy vectors should meet the following criteria: retaining the safety profile 
of naked DNA while displaying increased efficiency and decreased variability. From this per-
spective, non-viral methods of transfection present certain advantages such as relative ease of 
large-scale production, low risk of an adaptive immune response, versatility, and high safety 
profile.
Most of the non-viral vectors currently developed are based on polycationic molecules, which 
form interpolyelectrolyte complexes with the polyanionic nucleic acids. The complexes 
obtained generally allow for (1) efficient condensation of nucleic acids into small particles, (2) 
protection against degradation from nucleases, and (3) promotion of cellular uptake. These 
non-viral vectors usually consist of cationic lipids/liposomes (lipoplexes), cationic polymers 
(polyplexes), or a combination of both lipids and polymers (lipopolyplexes) [62,63].
Among these, vectors based on lipids are especially attractive due to the biocompatibility and 
biodegradability of lipids and phospholipids [64]. However, the toxicity displayed by cationic 
lipids, as well as the rapid clearance of positively charged lipoplexes, hampers further use in 
vivo of first-generation lipoplexes [64]. Coating the surface of lipoplexes, with hydrophilic 
polymers such as polyethylene glycol (PEG) can efficiently decrease their toxicity while 
increasing their circulation half-life [65]. Nonetheless, PEGylated lipoplexes often display 
reduced transfection efficiency due to diminished cellular uptake and can trigger anti-PEG 
IgM production, thus leading to accelerated blood clearance after readministration [66].
The tremendous diversity of shape, composition, and charge ratio of cationic polymers is a 
great asset when formulating polyplexes. Cationic polymers, which have been most widely 
used for cardiac gene delivery, include polyethylenimine, poly-(l-lysine), and dendrimers 
[67]. Despite their capacity to efficiently condense nucleic acids while preventing their degra-
dation by nucleases and improving endosomal escape, the resulting in vivo gene expression 
remains too low and, for some of them, cytotoxic effects are detected [62,67,68].
Although non-viral vectors have dramatically improved over the past decades, they remain 
underrepresented for cardiac gene delivery. Further improvements to increase transfection 
efficiency while reducing their cytotoxicity are much needed.
From this perspective, polymers displaying few or no positive charges could be the much 
needed formulation for cardiac gene therapy [69]. Poloxamers, which are non-ionic amphiphilic 
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block copolymers, were first reported by Lemieux et al. [70] as efficient formulations for mus-
cle gene delivery. Contrary to polycationic molecules, these delivery systems do not condense 
DNA into small particles and display no or weak interactions with nucleic acids [69,71]. Direct 
intramyocardial injection of poloxamer/DNA formulations showed no toxic effect towards the 
myocardium although gene expression remained limited and restricted to the injection site 
[71]. To increase the diffusion of poloxamer/DNA formulations into the myocardium, further 
experiments conducted in vivo on larger animals, through a clinically relevant administration 
route, were performed. As seen in Figure 3, this resulted in similar gene expression rate com-
pared to that of the same transgene delivered using an AAV1 vector. To provide more insight 
into poloxamer-based delivery systems, further studies addressing their mechanism of action 
as well as experiments evaluating the possibility to readminister these formulations should be 
carried out.
The principal limitation of most non-clinical studies and some clinical trials was the inability 
to efficiently transfer genes to the cardiac ventricles. Although in vivo experiments using small 
animals may show efficient gene transfer, many fundamental differences exist between small 
animal and human hearts. Large animal studies are best suited for comprehensive evalua-
tion at the preclinical stages of therapeutic development. It might seem obvious that delivery 
methods should meet all criteria of clinically relevant practices. Nevertheless, some preclini-
cal methods seem to lack this realism.
3.6. Administration strategies
With regards to the first step to translate in vivo gene transfer into clinically relevant gene 
therapy and based at least partly on the use of naked DNA, physical methods like direct 
intra-myocardial injections have demonstrated feasibility, but also limited efficiency. 
Derived from these pioneering steps, several refinements have been introduced over time. 
In the context of rhythm control, one should look with interest to techniques like gene 
painting [72]. Gene painting refers basically to an innovative technique aimed at a very 
Figure 3. Preclinical evaluation of intracoronary vector administration in large animals, for instance Beagle dogs. Similar 
amounts of cDNA were formulated differently. (A) Sample of a coronary contrast injection of the left main coronary 
artery in a dog heart highlighting the route of administration. (B) Mid-ventricular cross-section after AAV1 vectorization 
of a lacZ coding cDNA. (C) Mid-ventricular cross-section after polymer P85 vectorization of a lacZ coding cDNA. X-gal 
staining reveals lacZ gene expression (unpublished results).
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local gene transfer by a topical administration. Proof-of-concept studies have shown the 
efficiency of this approach in atrial fibrillation. Strategies based on ultrasound-targeted 
microbubble destruction could be a promising method for gene delivery [73]. Microbubbles 
are small (<5 μm) gas-filled voids that are generally stabilized by phospholipids or synthetic 
polymers. The use of microbubbles as gene vectors is based on the paradigm that destruc-
tion of the DNA-loaded microbubbles by ultrasounds will result in local transduction and 
still spare non-target areas. Percutaneous antegrade coronary injections are among the 
least invasive cardiac selective gene delivery methods and are rather broadly available. 
Intracoronary delivery allows diffuse transduction throughout the myocardium, but as such 
it is a highly inefficient process. However, dense regional gene transfer (>80% of myocytes 
in the target territory) is possible. Pharmacological manipulations to induce vasodilation 
and maximize vascular permeability in a specific coronary perfusion territory can greatly 
improve transfection efficiency [74]. Given the high perfusion velocity and the submaximal 
extent of the vascular bed, one has to maximize the duration of vector exposure to the local 
vasculature while minimizing the systemic distribution. Several options have been tested 
such as pharmacologically induced coronary artery dilation, blocking the venous return or 
developing a cardiac recirculation approach. Delivery methods based on cardiopulmonary 
bypass (CPB) with a closed-loop system can be used for cardiac gene therapy [75,76]. It 
might seem excessive to selectively prescribe CPB for gene delivery given the clearly inva-
sive nature of such a procedure. Nevertheless, one should not forget that many of the CM/
heart failure patients might need invasive procedures due to their clinical condition. Gene 
therapy should also be evaluated in the context of combination therapies. CM/heart failure 
presents as a syndrome with multiple pathophysiological facets. Early treatment of some 
specific aspects like atrial fibrillation by gene therapy might be as efficient as conventional 
cardioversion. Targeting the autonomous nervous system through gene therapy should be 
evaluated with reference to current beta-blockers. Inotropism might be improved by means 
of additive gene therapy, for example. However, beyond the diversity of gene therapy tar-
gets, combination with more conventional drugs might be improved by reinforcing the 
target pathways.
4. Conclusions
Gene therapy is emerging as a suitable alternative, with substantial progress in preclinical 
models of cardiovascular disorders. Despite the fact that none of the clinical trials, which 
investigated new treatments for CMs, has met their primary efficacy endpoints,  subanalysis, 
however, has demonstrated potential efficacy. Inadequate gene delivery remains one of the 
underlying causes behind failures seen in clinical trials. Higher transduction efficiency is 
needed to achieve therapeutic effects. Use of block copolymers in gene delivery is a promising 
area of research, in which new and important developments are expected.
CMs can serve as a disease model for several aspects when it comes to the development of 
gene therapy strategies in the context of cardiac diseases, since they also engulf inherited 
diseases like acquired disorders.
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The emphasis on gene therapies was initially focused on inherited diseases notably rescuing 
cardiac phenotype by introducing a functional allele in the context of recessive disorders. 
Even gene therapies that would only help a couple of thousand people would be a remarkable 
achievement.
More recently the concept of gene therapy has been extended to a larger perspective, includ-
ing the reprogramming of failing myocardial cells beyond inherited diseases. Several non-
clinical studies have supported the concept, but the true challenge of gene therapy for CM 
remains translation into the clinic. Sticking to the old paradigm that a drug substance can 
only become a medicinal drug product, if one is able to formulate and administer it, it seems 
more obvious that gene therapy has to be clinically oriented. Treating the failing heart implies 
several strong constraints linked to the anatomy and physiology of the heart. Successful gene 
therapy approaches in other diseases support the notion, but cannot fully address the under-
lying specific challenges facing cardiac gene delivery.
The development of robust administration techniques and improved formulations are 
therefore needed before cardiac gene therapy can be integrated into the therapeutic 
armamentarium.
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